Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YM155 plus Rituximab in Relapsed/Refractory B-cell NHL
NCT01007292Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2009
- Primary completion
- Mar 2013
- Modality
- Classical Binding Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of sepantronium in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Astellas Pharma. Started Nov 2009; status: completed.
02
Drugs
sepantronium
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01007292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01007292.